Luciana Borio, M.D., is a Venture Partner at ARCH Venture Partners where she advises on and helps develop new investment opportunities related to biologics manufacturing, clinical trials, novel therapies and areas with large unmet clinical needs.Dr. Borio specializes in biodefense, emerging infectious diseases, medical product development, and complex public health emergencies. Prior to ARCH, she was an SVP at In-Q-Tel, an independent investment firm that works to deliver innovative technology solutions to support the U.S. Intelligence Community. Past positions include serving as a member of President Biden’s transition COVID-19 Advisory Board and Director for Medical and Biodefense Preparedness at the National Security Council (2017-2019), where she coordinated the response to the Ebola epidemic in West Africa, efforts to combat antimicrobial resistance, and the development of an Executive Order to modernize America’s influenza vaccines. Prior to that, she was the Acting Chief Scientist of the FDA (2015-2017) and the Assistant Commissioner for Counterterrorism Policy of the FDA (2010-2017). Dr. Borio is an adjunct Assistant Professor of Medicine at Johns Hopkins (2003-present), where she continues to practice medicine. She is also a senior fellow for global health at the Council on Foreign Relations. Dr. Borio obtained her M.D. from George Washington University, did her residency in internal medicine at New York-Presbyterian/Weill Cornell, and a combined fellowship in infectious diseases at Johns Hopkins and critical care at the National Institutes of Health.
